OBJECTIVES: To determine whether risk reduction of statins for Alzheimer's disease (AD) varies by age or presence of apolipoprotein E (APOE) epsilon4 allele. DESIGN: A cohort of cognitively intact elderly participants was assessed biennially for dementia and AD. SETTING: Community based. PARTICIPANTS: Three thousand three hundred ninety-two members of a health maintenance organization (HMO) aged 65 and older and without dementia. MEASUREMENTS: Statin use was identified from the HMO pharmacy database, and proportional hazards models were applied with statin use as a time-dependent covariate to assess the association between statins and AD and the modifying effects of age and the APOE epsilon4 allele. RESULTS: Over an average of 6.1 years of follow-up of 3,099 participants, 263 participants developed probable AD. The adjusted hazard ratio (aHR) for statin use was 0.62 (95% confidence interval (CI)=0.40-0.97) for AD in models including demographic characteristics and vascular risk factors as covariates. The strength of the association between statins and AD diminished with age (statin-by-age at entry interaction P=.04); the aHR in those younger than 80 was 0.44 (95% CI=0.25-0.78), versus 1.22 (95% CI=0.61-2.42) for aged 80 and older. The interaction term for statin use-by-APOE epsilon4 was not significant (P=.65). CONCLUSION: This enlarged study confirms earlier findings that statin therapy in early old age, but not in late age, may be associated with a lower risk of AD. The relationship between statin use and AD was consistent across APOE genotypes.
OBJECTIVES: To determine whether risk reduction of statins for Alzheimer's disease (AD) varies by age or presence of apolipoprotein E (APOE) epsilon4 allele. DESIGN: A cohort of cognitively intact elderly participants was assessed biennially for dementia and AD. SETTING: Community based. PARTICIPANTS: Three thousand three hundred ninety-two members of a health maintenance organization (HMO) aged 65 and older and without dementia. MEASUREMENTS: Statin use was identified from the HMO pharmacy database, and proportional hazards models were applied with statin use as a time-dependent covariate to assess the association between statins and AD and the modifying effects of age and the APOE epsilon4 allele. RESULTS: Over an average of 6.1 years of follow-up of 3,099 participants, 263 participants developed probable AD. The adjusted hazard ratio (aHR) for statin use was 0.62 (95% confidence interval (CI)=0.40-0.97) for AD in models including demographic characteristics and vascular risk factors as covariates. The strength of the association between statins and AD diminished with age (statin-by-age at entry interaction P=.04); the aHR in those younger than 80 was 0.44 (95% CI=0.25-0.78), versus 1.22 (95% CI=0.61-2.42) for aged 80 and older. The interaction term for statin use-by-APOE epsilon4 was not significant (P=.65). CONCLUSION: This enlarged study confirms earlier findings that statin therapy in early old age, but not in late age, may be associated with a lower risk of AD. The relationship between statin use and AD was consistent across APOE genotypes.
Authors: Mikael Simons; Frank Schwärzler; Dieter Lütjohann; Klaus von Bergmann; Konrad Beyreuther; Johannes Dichgans; Henning Wormstall; Tobias Hartmann; Jörg B Schulz Journal: Ann Neurol Date: 2002-09 Impact factor: 10.422
Authors: Thomas D Rea; John C Breitner; Bruce M Psaty; Annette L Fitzpatrick; Oscar L Lopez; Anne B Newman; William R Hazzard; Peter P Zandi; Gregory L Burke; Constantine G Lyketsos; Charles Bernick; Lewis H Kuller Journal: Arch Neurol Date: 2005-07
Authors: G Li; E B Larson; J A Sonnen; J B Shofer; E C Petrie; A Schantz; E R Peskind; M A Raskind; J C S Breitner; T J Montine Journal: Neurology Date: 2007-08-28 Impact factor: 9.910
Authors: L U Gerdes; C Gerdes; K Kervinen; M Savolainen; I C Klausen; P S Hansen; Y A Kesäniemi; O Faergeman Journal: Circulation Date: 2000-03-28 Impact factor: 29.690
Authors: C Dufouil; F Richard; N Fiévet; J F Dartigues; K Ritchie; C Tzourio; P Amouyel; A Alpérovitch Journal: Neurology Date: 2005-05-10 Impact factor: 9.910
Authors: G Li; R Higdon; W A Kukull; E Peskind; K Van Valen Moore; D Tsuang; G van Belle; W McCormick; J D Bowen; L Teri; G D Schellenberg; E B Larson Journal: Neurology Date: 2004-11-09 Impact factor: 9.910
Authors: Peter P Zandi; D Larry Sparks; Ara S Khachaturian; Joann Tschanz; Maria Norton; Martin Steinberg; Kathleen A Welsh-Bohmer; John C S Breitner Journal: Arch Gen Psychiatry Date: 2005-02
Authors: Jean Schmidt; Tanaz A Kermani; Francesco Muratore; Cynthia S Crowson; Eric L Matteson; Kenneth J Warrington Journal: J Rheumatol Date: 2013-04-01 Impact factor: 4.666